PhRMA Slams FTC's Rationale For Targeting Drugmakers

Law360, New York (March 25, 2014, 8:53 PM EDT) -- The Pharmaceutical Research and Manufacturers of America on Monday blasted the Federal Trade Commission’s argument that the agency has authority to issue industry-specific requirements and urged a D.C. federal judge to vacate a rule requiring pharmaceutical companies to report more exclusive patent licenses for approval under federal merger law.

In its opposition to the FTC’s bid for summary judgment, PhRMA claimed the agency did not have the power under the Hart-Scott-Rodino Act to issue a rule requiring pharmaceutical companies to report more exclusive patent licenses for...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA v. FEDERAL TRADE COMMISSION


Case Number

1:13-cv-01974

Court

District Of Columbia

Nature of Suit

Administrative Procedure Act/Review or Appeal of Agency Decision

Judge

Beryl A. Howell

Date Filed

December 11, 2013

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.